60 related articles for article (PubMed ID: 30679919)
1. Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management.
Eljilany I; Elarref M; Shallik N; Elzouki AN; Bader L; El-Bardissy A; Abdelsamad O; Al-Badriyeh D; Cavallari LH; Elewa H
Pharmgenomics Pers Med; 2021; 14():1069-1080. PubMed ID: 34483679
[TBL] [Abstract][Full Text] [Related]
2. Variants in
Alghamdi MA; Al-Eitan L; Alkhatib R; Al-Assi A; Almasri A; Aljamal H; Aman H; Khasawneh R
Int J Gen Med; 2021; 14():1093-1100. PubMed ID: 33790638
[TBL] [Abstract][Full Text] [Related]
3. Influence of
Al-Eitan LN; Almasri AY; Alnaamneh AH; Aman HA; Alrabadi NN; Khasawneh RH; Alghamdi MA
Int J Med Sci; 2021; 18(3):826-834. PubMed ID: 33437219
[TBL] [Abstract][Full Text] [Related]
4. Influence of PSRC1, CELSR2, and SORT1 Gene Polymorphisms on the Variability of Warfarin Dosage and Susceptibility to Cardiovascular Disease.
Al-Eitan LN; Elsaqa BZ; Almasri AY; Aman HA; Khasawneh RH; Alghamdi MA
Pharmgenomics Pers Med; 2020; 13():619-632. PubMed ID: 33235484
[TBL] [Abstract][Full Text] [Related]
5. Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan.
Al-Eitan LN; Rababa'h DM; Hakooz NM; Alghamdi MA; Dajani RB
J Pers Med; 2020 Jan; 10(1):. PubMed ID: 31935801
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
[TBL] [Abstract][Full Text] [Related]
7. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
Yip VL; Pirmohamed M
Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
[TBL] [Abstract][Full Text] [Related]
8. Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy.
Al-Eitan LN; Almasri AY; Al-Habahbeh SO
Pharmgenomics Pers Med; 2019; 12():1-8. PubMed ID: 30679919
[TBL] [Abstract][Full Text] [Related]
9. Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease.
Al-Eitan LN; Almasri AY; Al-Habahbeh SO
Pharmgenomics Pers Med; 2019; 12():15-22. PubMed ID: 30962704
[TBL] [Abstract][Full Text] [Related]
10. Influence of
Al-Eitan LN; Almasri AY; Khasawneh RH; Alghamdi MA
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32916786
[TBL] [Abstract][Full Text] [Related]
11. Effect of MEF2A and SLC22A3-LPAL2-LPA gene polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients.
Al-Eitan LN; Almasri AY; Alnaamneh AH; Mihyar A
PLoS One; 2023; 18(11):e0294226. PubMed ID: 37948393
[TBL] [Abstract][Full Text] [Related]
12. Impact of
Al-Eitan LN; Almasri AY; Khasawneh RH
Genes (Basel); 2018 Nov; 9(12):. PubMed ID: 30486437
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
